[ad_1] Inflammatory bowel disease (IBD) often significantly affects the daily lives and quality of life of those affected. At an information event at the Brothers Hospital in Trier, it appeared that most …
Read More »Janssen's STELARA® (ustekinumab) Shows Lasting Efficacy to Improve Clinical Remission Rates in Patients with Moderate to Severe Crohn's Disease over a Three-Year Period
[ad_1] New study data also confirm STELARA's effectiveness® (Ustekinumab) in tumor necrosis factor (TNF) antagonist-naive patients or those who do not tolerate this Janssen Pharmaceuticals of Johnson & Johnson today announced new …
Read More »